Open-label phase 2 study results of FS118, a LAG-3/PD-L1 bispecific antibody, in patients with relapsed/refractory diffuse large B-cell lymphoma
Last Updated: Tuesday, December 17, 2024
The anti–LAG-3/PD-L1 bispecific antibody FS118 showed modest efficacy among patients with relapsed/refractory DLBCL who had previously received at least 2 systemic treatment regimens. This phase 2 data—presented during the 2024 American Society of Hematology Annual Meeting—demonstrated a 20% objective response rate (n = 2; 95% CI: 2.5%-55.6%) with no dose-limiting toxicities.
Advertisement
News & Literature Highlights
